뉴스&공지

뉴스

GENIXCURE selects dementia treatment development tasks by the Dementia Overcoming Research and Development Project

2021-01-11

GENIXCURE said that the Alzheimer's disease gene therapy pipeline "ANL-101" was finally selected as a non-clinical support project for the development of dementia treatments by the Dementia Overcoming Research and Development Project.


The Dementia Overcoming Research and Development Project is a research and development support project on the prevention, diagnosis, and treatment of dementia organized by the Ministry of Health and Welfare and the Ministry of Science and ICT under the National Dementia Research and Development Strategy.


This is the first support project since the launch of the project group this year, and the project group announced in October 22 tasks in a total of 9 fields, including prevention, diagnosis, and treatment development.


Since then, it has been reported that national and public research institutes or private corporate research institutes that meet the direction of R&D support for "discovering core technologies to overcome dementia through the introduction of innovative and creative research topics and techniques" were strictly reviewed and selected.


In particular, the non-clinical task of developing dementia treatments selected by GENIXCURE is known to have attracted overwhelming support from research institutes compared to other tasks with a high competition rate of about 20 to 1.


In addition to Yonsei University's Industry-Academic Cooperation Foundation and Korea Institute of Science and Technology, GENIXCURE was selected as the only nonclinical research institute to support non-clinical sectors. The company, including the company's highly evaluated first-in-class AD treatment, confirmed the possibility of dementia. 


GENIXCURE is a degenerative brain disease gene therapy R&D company based on Kim Keetae's research to determine the correlation between microRNA and aging. Its main new drug development pipeline is CNS diseases such as mild cognitive impairment, Parkinson's disease, and epilepsy.


Since its establishment in 2019, GENIXCURE, which has been in charge of management and R&D by Moon Hong-sung and CSO Kim Keetae, has completed 2 billion won from POSCO Technology Investment in October and is currently in the process of Series A. 


An GENIXCURE official said, "We are very proud that the government has been selected as one of the first support projects of the newly established Dementia Overcoming Research and Development Project to identify and strategically promote one area of dementia overcoming, and we will focus more on realizing the value of 'beautiful aging and healthy longevity'."